Abstract
Glucagon-like peptide 1 agonists (GLP1s) and the novel glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 agonist are effective drugs for reducing A1C and weight in patients with type 2 diabetes. However, clinicians may find it difficult to discern which drug to prescribe in specific clinical scenarios. This article discusses evidence-based clinical use of these drugs.
Copyright © 2024 American Academy of Physician Associates.
MeSH terms
-
Diabetes Mellitus, Type 2* / drug therapy
-
Exenatide / administration & dosage
-
Exenatide / therapeutic use
-
Gastric Inhibitory Polypeptide / agonists
-
Gastric Inhibitory Polypeptide / therapeutic use
-
Glucagon-Like Peptide 1* / agonists
-
Glucagon-Like Peptide-1 Receptor / agonists
-
Glycated Hemoglobin
-
Humans
-
Hypoglycemic Agents* / therapeutic use
-
Liraglutide / therapeutic use
-
Peptides / therapeutic use
-
Weight Loss* / drug effects
Substances
-
Glucagon-Like Peptide 1
-
Hypoglycemic Agents
-
Liraglutide
-
Gastric Inhibitory Polypeptide
-
Exenatide
-
Peptides
-
Glycated Hemoglobin
-
Glucagon-Like Peptide-1 Receptor